Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Core Viewpoint - Senseonics Holdings, Inc. is conducting a public offering of 100 million shares at $0.50 per share, aiming to raise $50 million before expenses [1] Group 1: Offering Details - The public offering is priced at $0.50 per share, with gross proceeds expected to be $50 million [1] - Underwriters have a 30-day option to purchase an additional 15 million shares at the same price [1] - The offering is set to close on May 19, 2025, pending customary closing conditions [1] Group 2: Underwriters - TD Cowen and Barclays are the joint book-running managers for the offering [2] - RBC Capital Markets and Lake Street are acting as bookrunners [2] Group 3: Concurrent Private Placement - Abbott Laboratories will purchase shares in a separate private placement at $0.50 per share, representing 4.99% of Senseonics' outstanding common stock post-offering [4] - The Concurrent Private Placement is expected to close on May 21, 2025, subject to the public offering's closing [4] Group 4: Use of Proceeds - The net proceeds from both the public offering and the Concurrent Private Placement will be used to fund the launch of Eversense 365, ongoing product development, working capital, and general corporate purposes [5] Group 5: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management [7] - The company's products include Eversense® 365 and Eversense® E3, which feature a small sensor that communicates glucose data to a mobile app every 5 minutes [7]